Immune Design competitors

Immune Design's competitors include Aptevo Therapeutics, Ourotech, Aeglea Biotherapeutics and Heat Biologics
Add company...
Immune Design
Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases.
Aptevo Therapeutics
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market.
Ourotech
Ourotech is changing the way cancer drugs are tested for the most innovative treatments.
Aeglea Biotherapeutics
Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer.
Heat Biologics
Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic “off-the-shelf” cell based immunotherapy to treat patients with a wide array of cancers and infectious diseases.
Founding Date
Founding Date
2008
Founding Date
2016
Founding Date
2015
Founding Date
2013
Founding Date
2008
Type
Type
Public
Type
Public
Type
Private
Type
Public
Type
Public
Tags
Locations
Locations
Seattle, US HQ
South San Francisco, US
Locations
Seattle, US HQ
Locations
Waterloo, CA HQ
Locations
Austin, US HQ
Locations
Durham, US HQ
Employees
Employees
50
Employees
118
Employees
433% increase
Employees
4518% increase
Employees
19
Valuation ($)
Valuation ($)
216.6 m
Valuation ($)
111.6 m
Valuation ($)
N/A
Valuation ($)
227.3 m
Valuation ($)
43.7 m
Facebook likes
Facebook likes
N/A
Facebook likes
N/A
Facebook likes
504
Facebook likes
N/A
Facebook likes
110

Financial

Revenue (est.)
Revenue (est.)
$7.2m (FY, 2017)
Revenue (est.)
$14.7m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
N/A
Cost of goods
Cost of goods
$84k (FY, 2017)
Cost of goods
$5m (FY, 2017)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$7.1m (FY, 2017)
Gross profit
$9.6m (FY, 2017)
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($51.9m) (FY, 2017)
Net income
$7m (FY, 2017)
Net income
N/A
Net income
($27.2m) (FY, 2017)
Net income
($12.4m) (FY, 2017)

Operating

Phase I Trials Products
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Aptevo Therapeutics
HQ
Seattle, US
Employees
118

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market.

View company
Ourotech
HQ
Waterloo, CA
Employees
4↑ 33% increase

Ourotech is changing the way cancer drugs are tested for the most innovative treatments.

View company
Aeglea Biotherapeutics
HQ
Austin, US
Employees
45↑ 18% increase

Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer.

View company
Heat Biologics
HQ
Durham, US
Employees
19

Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic “off-the-shelf” cell based immunotherapy to treat patients with a wide array of cancers and infectious diseases.

View company